This decision also resulted in a substantial reduction in Baird’s price target for Instil Bio, dropping from $180.00 to $7.00. Following this announcement, Instil Bio’s subsidiary, Axion Bio, has ...
Instil Bio reports ongoing trials for AXN-2510/IMM2510 in NSCLC; financial results show cash reserves enabling operations beyond 2026. Instil Bio, Inc. announced ongoing enrollment for a clinical ...
ImmuneOnco plans to release clinical data for AXN-2510/IMM2510 in NSCLC in 2025, initiating trials in China and the U.S. Instil Bio, Inc. announced plans for the clinical development of its ...
The company revealed it has discontinued the licenses for its AXN-2510 and AXN-27M drug candidates with ImmuneOnco, leading to a downgrade by Baird from Outperform to Neutral. This decision also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results